Edition:
United States

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

22.90USD
24 Feb 2017
Change (% chg)

$-0.65 (-2.76%)
Prev Close
$23.55
Open
$23.35
Day's High
$23.45
Day's Low
$22.45
Volume
106,833
Avg. Vol
208,076
52-wk High
$39.95
52-wk Low
$16.75

LCI.N

Chart for LCI.N

About

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June... (more)

Overall

Beta: 2.42
Market Cap(Mil.): $851.64
Shares Outstanding(Mil.): 37.19
Dividend: --
Yield (%): --

Financials

  LCI.N Industry Sector
P/E (TTM): -- 28.84 29.63
EPS (TTM): -0.64 -- --
ROI: -1.53 13.44 12.96
ROE: -4.26 14.34 14.11

BRIEF-Lannett Co says FDA agreed to delay submission deadline for Methylphenidate ER tablets

* Lannett provides further update on methylphenidate er tablets

Feb 22 2017

BRIEF-Lannett announces successful completion of ERP system extraction

* Lannett announces successful completion of ERP system extraction Source text for Eikon: Further company coverage:

Feb 07 2017

BRIEF-Lannett's subsidiary to launch $50 mln expansion - SEC filing

* Lannett Company Inc - Cody Laboratories, a wholly owned subsidiary of company, would be launching a $50 million expansion to its facilities - SEC filing Source text for Eikon: Further company coverage:

Jan 31 2017

BRIEF-Lannett announces approval for Metaxalone Tablets

* Lannett announces approval for Metaxalone Tablets USP, 800 mg

Nov 28 2016

BRIEF-Lannett announces approval for memantine hydrochloride tablets USP, 5 mg and 10 mg

* Lannett announces approval for memantine hydrochloride tablets usp, 5 mg and 10 mg

Nov 14 2016

BRIEF-James Flynn reports 5.43 pct passive stake in Lannett Company

* James flynn reports 5.43 percent passive stake in lannett company inc as of november 8 - sec filing Source text : http://bit.ly/2eFtqPg Further company coverage:

Nov 10 2016

BRIEF-Snow Capital Management reports 5.7 pct passive stake in Lannett Co

* Snow capital management lp reports 5.7 percent passive stake in lannett company inc as of october 6 - sec filing Source text : http://bit.ly/2ekC6zm Further company coverage:

Nov 09 2016

BRIEF-Lannett reports fiscal 2017 Q1 financial results

* Lannett Company Inc sees 2017 GAAP net sales $675 million to $685 million; down from $690 million to $700 million

Nov 03 2016

BRIEF-Lannett expects to report impairment charge related to methylphenidate of about $65 mln in results of operations for three months ended Sept 30

* Lannett-Concluded it expects to report impairment charge related to methylphenidate of about $65 million in results of operations for three months ended Sept 30 Source text: [http://bit.ly/2ffdfOg] Further company coverage:

Oct 28 2016

BRIEF-Lannett announces successful phase III clinical trial results for proprietary C-Topical product

* Lannett announces successful phase III clinical trial results for proprietary C-Topical product

Oct 27 2016

More From Around the Web

Competitors

  Price Chg
AbbVie Inc (ABBV.N) $62.09 +0.15
Pfizer Limited (PFIZ.NS) Rs1,774.45 -2.15
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs2,887.40 -15.80

Earnings vs. Estimates